EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Integrated management strategies for benign prostatic hyperplasia

Yingchen Zhou, Qiao Luo, Ruixiao Wang, Dongxiang Zheng, Yaqing Xiong, Jiao Zuo, Shusheng Wang, Liang Zhong

Frontiers in Urology · 13.10.2025 · 5

DOI: 10.3389/fruro.2025.1641171 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Urology, online erschienen am 13.10.2025. Verfasst von Yingchen Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Surgery, Zhongshan Hospital of Traditional Chinese Medicine, Zhongshan, China. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Benign prostatic hyperplasia (BPH) is a common condition in aging men, leading to lower urinary tract symptoms (LUTS) that affect quality of life. Treatment options have evolved from invasive surgeries to a combination of pharmacological therapies, minimally invasive surgical therapies (MISTs), and standard surgical procedures. Medications such as α-blockers, 5-alpha reductase inhibitors (5-ARIs), and phosphodiesterase-5 inhibitors (PDE5i) are the first-line treatment for mild-to-moderate BPH, while MISTs like Rezūm, UroLift, Aquablation, and prostatic artery embolization (PAE) provide less invasive alternatives with shorter recovery times. For larger prostates, TURP and HoLEP remain the gold standards, offering effective long-term symptom relief despite some risks. Future advancements in BPH treatment focus on robotic-assisted surgery, AI-guided treatment selection, hybrid therapies, and regenerative medicine, aiming to enhance precision, reduce complications, and improve patient outcomes. This review summarizes current BPH management strategies and explores future innovations in the field.

Schlagwörter

Stichwörter der Autor:innen

benign prostatic hyperplasialower urinary tract symptomsmedicationsminimally invasive surgical therapiesprostate

Autor:innen und Institutionen

  • Department of Urology Surgery, Zhongshan Hospital of Traditional Chinese Medicine, Zhongshan, China.
  • School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, Macau, Macao SAR, China.
  • The Synthesis Team of the Transformation Research Institute, Shenzhen Second People's Hospital, Shenzhen, China.
  • Department of Urology Surgery, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China.

Zitieren

APA

Zhou, Y., Luo, Q., Wang, R., Zheng, D., Xiong, Y., Zuo, J., Wang, S., & Zhong, L. (2025). Integrated management strategies for benign prostatic hyperplasia. Frontiers in Urology, 5. https://doi.org/10.3389/fruro.2025.1641171

Vancouver

Zhou Y, Luo Q, Wang R, Zheng D, Xiong Y, Zuo J, et al. Integrated management strategies for benign prostatic hyperplasia. Frontiers in Urology. 2025;5. doi:10.3389/fruro.2025.1641171

BibTeX
@article{Zhou2025,
  author = {Zhou, Yingchen and Luo, Qiao and Wang, Ruixiao and Zheng, Dongxiang and Xiong, Yaqing and Zuo, Jiao and Wang, Shusheng and Zhong, Liang},
  title = {Integrated management strategies for benign prostatic hyperplasia},
  journal = {Frontiers in Urology},
  year = {2025},
  volume = {5},
  doi = {10.3389/fruro.2025.1641171}
}
Kostenlos starten →